IDH1 Mutation Test for Brain Tumors | Lahalak Platform
This analysis aids in precise classification of gliomas by detecting the IDH1 mutation, providing clear insights into prognosis and opening doors for personalized targeted therapy options.
Scientific name: IDH1 Immunohistochemistry Test
Immunohistochemical (IHC) assays for IDH1 aim to detect the expression of the mutant isocitrate dehydrogenase 1 (IDH1R132H) variant, which accounts for approximately 90% of all IDH1 mutations in central nervous system tumors. Specific antibodies are used to detect the mutant protein within the nuclei and cytoplasm of tumor cells. This mutation is a...
Service type
Laboratory test (Tissue)
Duration
10-15 minutes
Fasting
Fasting is not required
Included Services
- Detailed analysis to detect the IDH1 R132H mutation in brain glioma tissue samples
- Consult a neuropathologist to interpret the results.
- Personal support services from Lahalak
Medical Service Information
Conditions & Notices
- Fasting is not required, as the sample is a surgical tissue sample from the brain.
- The tissue sample must be immediately preserved in 10% formalin and processed in a timely manner (no excessive fixation) to preserve the antigens.
- This analysis is routinely requested for all adult gliomas as part of mandatory molecular diagnosis.
- It is often requested as part of a comprehensive molecular package for brain tumors that also includes ATRX, p53, and MGMT promoter methylation status.
Medical services you might also like
